6 Shaanxi International Trust Co.Ltd(000563) announced on March 18 that the company completed the first batch of covid-19 virus treatment drug paxlovid? We are fully cooperating with the state in the fight against covid-19 epidemic.
It is reported that 6 Shaanxi International Trust Co.Ltd(000563) signed an agreement with Pfizer on March 9 to be responsible for the covid-19 virus treatment drug paxlovid of Pfizer during the term of the agreement (2022)? Business operation in the Chinese mainland market. On February 11, 2022, the State Food and Drug Administration approved the import registration of the drug with conditions. In March 15th, the National Health Council released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth), which was included in the ninth edition of the diagnosis and treatment plan, but has not yet entered the national health insurance. China Meheco Group Co.Ltd(600056) said that if it is included in the national medical insurance, it may have an impact on the sales price. The final use and sales of the product are affected by factors such as epidemic prevention and control, there is great uncertainty, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on its recent business performance.
China Meheco Group Co.Ltd(600056) from March 2 to March 18, the stock price has increased by nearly 200% for 10 times in 13 trading days, and has touched the stock trading change for the fifth time. The company said that its recent share price increase may have exceeded the impact of relevant matters on the company’s performance, and there may be irrational investment.
